GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eton Pharmaceuticals Inc (NAS:ETON) » Definitions » Price-to-Tangible-Book

Eton Pharmaceuticals (Eton Pharmaceuticals) Price-to-Tangible-Book : 8.21 (As of May. 12, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Eton Pharmaceuticals Price-to-Tangible-Book?

As of today (2024-05-12), Eton Pharmaceuticals's share price is $3.43. Eton Pharmaceuticals's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $0.42. Hence, Eton Pharmaceuticals's Price to Tangible Book Ratio of today is 8.21.

The historical rank and industry rank for Eton Pharmaceuticals's Price-to-Tangible-Book or its related term are showing as below:

ETON' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.1   Med: 9.54   Max: 13.09
Current: 8.17

During the past 7 years, Eton Pharmaceuticals's highest Price to Tangible Book Ratio was 13.09. The lowest was 4.10. And the median was 9.54.

ETON's Price-to-Tangible-Book is ranked worse than
87.6% of 871 companies
in the Drug Manufacturers industry
Industry Median: 2.41 vs ETON: 8.17

A closely related ratio is called PB Ratio. As of today, Eton Pharmaceuticals's share price is $3.43. Eton Pharmaceuticals's Book Value per Sharefor the quarter that ended in Dec. 2023 was $0.60. Hence, Eton Pharmaceuticals's P/B Ratio of today is 5.70.


Eton Pharmaceuticals Price-to-Tangible-Book Historical Data

The historical data trend for Eton Pharmaceuticals's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eton Pharmaceuticals Price-to-Tangible-Book Chart

Eton Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
Get a 7-Day Free Trial 13.09 13.09 7.54 8.60 10.48

Eton Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.60 14.75 7.24 8.44 10.48

Competitive Comparison of Eton Pharmaceuticals's Price-to-Tangible-Book

For the Drug Manufacturers - Specialty & Generic subindustry, Eton Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eton Pharmaceuticals's Price-to-Tangible-Book Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eton Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Eton Pharmaceuticals's Price-to-Tangible-Book falls into.



Eton Pharmaceuticals Price-to-Tangible-Book Calculation

Eton Pharmaceuticals's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Dec. 2023 )
=3.43/0.418
=8.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Eton Pharmaceuticals Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Eton Pharmaceuticals's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Eton Pharmaceuticals (Eton Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
21925 West Field Parkway, Suite 235, Deer Park, IL, USA, 60010-7278
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has a diversified pipeline of around eleven product candidates in various stages of development.
Executives
David Krempa officer: Chief Business Officer 29125 W FIELD PARKWAY, SUITE 235, DEER PARK IL 60010
Sean Brynjelsen director, officer: President & CEO C/O ETON PHARMACEUTICALS, INC., 21925 W FIELD PKWY #235, DEER PARK IL 60010
James R. Gruber officer: Chief Financial Officer 618 AMES STREET, LIBERTYVILLE IL 60048
Opaleye Management Inc. 10 percent owner ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
William Wilson Troutman officer: CFO, Treasurer & Secretary 21925 W FIELD PARKWAY, SUITE 235, DEER PARK IL 60010
Imprimis Pharmaceuticals, Inc. 10 percent owner 102 WOODMONT BLVD, SUITE 610, NASHVILLE TN 37215
Jennifer Mckie Adams director 5410 TENNESSEE AVE, NASHVILLE TN 37209
Charles J Casamento director 99 BELBROOK WAY, ATHERTON CA 94027
Norbert G Riedel director BAXTER INTERNATIONAL INC, ONE BAXTER PKWY DF2-1W, DEERFIELD IL 60015
Mark L Baum director C/O IMPRIMIS PHARMACEUTICALS, INC, 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130
Paul V Maier director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121